[
    {
        "id": 2441,
        "drug_name": "YESCARTA - Axicabtagene ciloleucel - (ZUMA-5)",
        "clinical_trial_id": "NCT03105336",
        "has_trial_insight_page": 0,
        "indication": "Indolent B-Cell Non-Hodgkin Lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-03-05",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210305005624\/en\/",
        "note": "FDA approval announced March 5, 2021.",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4860,
        "drug_name": "ARCALYST (rilonacept)",
        "clinical_trial_id": "NCT03737110",
        "has_trial_insight_page": 0,
        "indication": "Pericarditis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-03-18",
        "link": "https:\/\/www.benzinga.com\/pressreleases\/21\/03\/g20244361\/kiniksa-announces-fda-approval-of-arcalyst-rilonacept-for-recurrent-pericarditis",
        "note": "FDA approval announced March 18, 2021.",
        "company_entity_id": 556,
        "company_ticker": "KNSA",
        "company_name": "Kiniksa Pharmaceuticals Ltd.",
        "company_price": "20.4400",
        "company_change": 0.1,
        "company_percent_change": 0.49,
        "company_optionable": 1,
        "company_number_of_shares": 70615022,
        "price_change_sparkline": [
            [
                17.63,
                1706677200
            ],
            [
                18.21,
                1706763600
            ],
            [
                18.38,
                1706850000
            ],
            [
                18.49,
                1707109200
            ],
            [
                18.49,
                1707195600
            ],
            [
                18.12,
                1707282000
            ],
            [
                19.02,
                1707368400
            ],
            [
                20.28,
                1707454800
            ],
            [
                20.55,
                1707714000
            ],
            [
                19.86,
                1707800400
            ],
            [
                19.89,
                1707886800
            ],
            [
                20.17,
                1707973200
            ],
            [
                19.94,
                1708059600
            ],
            [
                19.92,
                1708405200
            ],
            [
                19.96,
                1708491600
            ],
            [
                19.72,
                1708578000
            ],
            [
                20,
                1708664400
            ],
            [
                20.16,
                1708923600
            ],
            [
                20.89,
                1709010000
            ],
            [
                20.36,
                1709096400
            ],
            [
                21.14,
                1709182800
            ],
            [
                21.74,
                1709269200
            ],
            [
                20.19,
                1709528400
            ],
            [
                20.18,
                1709614800
            ],
            [
                21,
                1709701200
            ],
            [
                21.26,
                1709787600
            ],
            [
                20.81,
                1709874000
            ],
            [
                20.34,
                1710129600
            ],
            [
                20.44,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5124,
        "drug_name": "Dasiglucagon",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Severe hypoglycemia in diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-03-22",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/03\/22\/2197267\/0\/en\/Zealand-Pharma-Announces-FDA-Approval-of-Zegalogue-dasiglucagon-injection-for-the-Treatment-of-Severe-Hypoglycemia-in-People-with-Diabetes.html",
        "note": "FDA approval announced March 22, 2021.",
        "company_entity_id": 2257,
        "company_ticker": "ZLDPF",
        "company_name": "Zealand Pharma A\/S.",
        "company_price": "103.2000",
        "company_change": 2.25,
        "company_percent_change": 2.23,
        "company_optionable": 0,
        "company_number_of_shares": 62512622,
        "price_change_sparkline": [
            [
                68.65,
                1706677200
            ],
            [
                69,
                1706763600
            ],
            [
                67.96,
                1706850000
            ],
            [
                72.17,
                1707109200
            ],
            [
                69.27,
                1707195600
            ],
            [
                67.285,
                1707282000
            ],
            [
                68.44,
                1707368400
            ],
            [
                72.22,
                1707454800
            ],
            [
                69.5345,
                1707714000
            ],
            [
                68.88,
                1707800400
            ],
            [
                68.88,
                1707886800
            ],
            [
                70.544,
                1707973200
            ],
            [
                70.544,
                1708059600
            ],
            [
                70.544,
                1708405200
            ],
            [
                68.07,
                1708491600
            ],
            [
                67.93,
                1708578000
            ],
            [
                67.93,
                1708664400
            ],
            [
                103,
                1708923600
            ],
            [
                90,
                1709010000
            ],
            [
                94,
                1709096400
            ],
            [
                97,
                1709182800
            ],
            [
                95.9,
                1709269200
            ],
            [
                96.915,
                1709528400
            ],
            [
                100.876,
                1709614800
            ],
            [
                99.7,
                1709701200
            ],
            [
                111.19,
                1709787600
            ],
            [
                108.355,
                1709874000
            ],
            [
                100.9495,
                1710129600
            ],
            [
                103.2,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6979,
        "drug_name": "KEYTRUDA (pembrolizumab) + chemo",
        "clinical_trial_id": "NCT03189719",
        "has_trial_insight_page": 0,
        "indication": "Esophageal Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-03-23",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210323005359\/en\/",
        "note": "FDA approval announced March 23, 2021.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3104,
        "drug_name": "ABECMA (idecabtagene vicleucel)",
        "clinical_trial_id": "NCT03361748",
        "has_trial_insight_page": 0,
        "indication": "Relapsed\/refractory multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-03-26",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210326005507\/en\/",
        "note": "FDA approval announced March 26, 2021.",
        "company_entity_id": 68,
        "company_ticker": "BLUE",
        "company_name": "bluebird bio Inc.",
        "company_price": "1.3450",
        "company_change": -0.050000000000000044,
        "company_percent_change": -3.24,
        "company_optionable": 1,
        "company_number_of_shares": 109336211,
        "price_change_sparkline": [
            [
                1.02,
                1706677200
            ],
            [
                0.9987,
                1706763600
            ],
            [
                0.9561,
                1706850000
            ],
            [
                0.9052,
                1707109200
            ],
            [
                0.94,
                1707195600
            ],
            [
                0.9357,
                1707282000
            ],
            [
                1.05,
                1707368400
            ],
            [
                1.03,
                1707454800
            ],
            [
                1.09,
                1707714000
            ],
            [
                0.9826,
                1707800400
            ],
            [
                1.025,
                1707886800
            ],
            [
                1.08,
                1707973200
            ],
            [
                1.02,
                1708059600
            ],
            [
                1.1,
                1708405200
            ],
            [
                1.09,
                1708491600
            ],
            [
                1.18,
                1708578000
            ],
            [
                1.25,
                1708664400
            ],
            [
                1.46,
                1708923600
            ],
            [
                1.75,
                1709010000
            ],
            [
                1.68,
                1709096400
            ],
            [
                1.39,
                1709182800
            ],
            [
                1.565,
                1709269200
            ],
            [
                1.53,
                1709528400
            ],
            [
                1.39,
                1709614800
            ],
            [
                1.45,
                1709701200
            ],
            [
                1.45,
                1709787600
            ],
            [
                1.5,
                1709874000
            ],
            [
                1.39,
                1710129600
            ],
            [
                1.345,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3104,
        "drug_name": "ABECMA (idecabtagene vicleucel)",
        "clinical_trial_id": "NCT03361748",
        "has_trial_insight_page": 0,
        "indication": "Relapsed\/refractory multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-03-26",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210326005507\/en\/",
        "note": "FDA approval announced March 26, 2021.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2890,
        "drug_name": "VYXEOS (daunorubicin and cytarabine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acute myeloid leukemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-03-30",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/jazz-pharmaceuticals-announces-fda-approval-of-additional-indication-for-vyxeos-daunorubicin-and-cytarabine-for-the-treatment-of-secondary-acute-myeloid-leukemia-in-pediatric-patients-301259059.html",
        "note": "FDA approval for label extension to include children. ",
        "company_entity_id": 381,
        "company_ticker": "JAZZ",
        "company_name": "Jazz Pharmaceuticals plc",
        "company_price": "115.7900",
        "company_change": -0.84,
        "company_percent_change": -0.72,
        "company_optionable": 1,
        "company_number_of_shares": 62345283,
        "price_change_sparkline": [
            [
                122.72,
                1706677200
            ],
            [
                123.68,
                1706763600
            ],
            [
                122.9,
                1706850000
            ],
            [
                121.98,
                1707109200
            ],
            [
                124.71,
                1707195600
            ],
            [
                122.94,
                1707282000
            ],
            [
                122.67,
                1707368400
            ],
            [
                123.43,
                1707454800
            ],
            [
                124.24,
                1707714000
            ],
            [
                121.83,
                1707800400
            ],
            [
                122.24,
                1707886800
            ],
            [
                126.82,
                1707973200
            ],
            [
                126.78,
                1708059600
            ],
            [
                126.36,
                1708405200
            ],
            [
                128.42,
                1708491600
            ],
            [
                128.45,
                1708578000
            ],
            [
                132.28,
                1708664400
            ],
            [
                132.77,
                1708923600
            ],
            [
                132.26,
                1709010000
            ],
            [
                129.7,
                1709096400
            ],
            [
                118.9,
                1709182800
            ],
            [
                118.85,
                1709269200
            ],
            [
                117.53,
                1709528400
            ],
            [
                118.42,
                1709614800
            ],
            [
                117.19,
                1709701200
            ],
            [
                116.37,
                1709787600
            ],
            [
                117.53,
                1709874000
            ],
            [
                116.63,
                1710129600
            ],
            [
                115.79,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5683,
        "drug_name": "SARCLISA (isatuximab)",
        "clinical_trial_id": "NCT03275285",
        "has_trial_insight_page": 0,
        "indication": "Refractory Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-03-31",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/25506cf2-0c30-43ef-8eb3-62395dc4c613",
        "note": "FDA approval announced March 31, 2021.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2382,
        "drug_name": "TYVASO (treprostinil)",
        "clinical_trial_id": "NCT02630316",
        "has_trial_insight_page": 0,
        "indication": "Pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-04-01",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/united-therapeutics-announces-fda-approval-and-launch-of-tyvaso-for-the-treatment-of-pulmonary-hypertension-associated-with-interstitial-lung-disease-301260212.html",
        "note": "FDA approval announced April 1, 2021.",
        "company_entity_id": 300,
        "company_ticker": "UTHR",
        "company_name": "United Therapeutics Corporation",
        "company_price": "246.8700",
        "company_change": -2.64,
        "company_percent_change": -1.06,
        "company_optionable": 1,
        "company_number_of_shares": 47058545,
        "price_change_sparkline": [
            [
                214.78,
                1706677200
            ],
            [
                215.97,
                1706763600
            ],
            [
                213.41,
                1706850000
            ],
            [
                212.76,
                1707109200
            ],
            [
                214.95,
                1707195600
            ],
            [
                210.76,
                1707282000
            ],
            [
                211.74,
                1707368400
            ],
            [
                212.34,
                1707454800
            ],
            [
                216.25,
                1707714000
            ],
            [
                213.75,
                1707800400
            ],
            [
                214.43,
                1707886800
            ],
            [
                214.54,
                1707973200
            ],
            [
                214.73,
                1708059600
            ],
            [
                214.16,
                1708405200
            ],
            [
                219.18,
                1708491600
            ],
            [
                217.6,
                1708578000
            ],
            [
                227.03,
                1708664400
            ],
            [
                223.58,
                1708923600
            ],
            [
                226.75,
                1709010000
            ],
            [
                227.28,
                1709096400
            ],
            [
                225.64,
                1709182800
            ],
            [
                231.92,
                1709269200
            ],
            [
                228.74,
                1709528400
            ],
            [
                229.81,
                1709614800
            ],
            [
                236.97,
                1709701200
            ],
            [
                239.96,
                1709787600
            ],
            [
                243.05,
                1709874000
            ],
            [
                249.51,
                1710129600
            ],
            [
                246.87,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6627,
        "drug_name": "PRALUENT (alirocumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Homozygous familial hypercholesterolemia (HoFH) ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-04-01",
        "link": "https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol-0#:~:text=%5B4%2F1%2F2021%5D,that%20causes%20severely%20high%20cholesterol.&text=Patients%20with%20HoFH%20have%20two,way%20the%20body%20clears%20cholesterol.",
        "note": "FDA approval announced April 1, 2021.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3801,
        "drug_name": "QELBREE - viloxazine extended-release",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "ADHD",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-04-02",
        "link": "https:\/\/ir.supernus.com\/news-releases\/news-release-details\/supernus-announces-fda-approval-qelbreetm-spn-812-treatment-adhd",
        "note": "FDA approval announced April 2, 2021.",
        "company_entity_id": 287,
        "company_ticker": "SUPN",
        "company_name": "Supernus Pharmaceuticals Inc.",
        "company_price": "32.9200",
        "company_change": 0.49,
        "company_percent_change": 1.51,
        "company_optionable": 1,
        "company_number_of_shares": 54734956,
        "price_change_sparkline": [
            [
                27.68,
                1706677200
            ],
            [
                27.86,
                1706763600
            ],
            [
                27.67,
                1706850000
            ],
            [
                27.31,
                1707109200
            ],
            [
                28.31,
                1707195600
            ],
            [
                27.24,
                1707282000
            ],
            [
                27.9,
                1707368400
            ],
            [
                27.91,
                1707454800
            ],
            [
                28.35,
                1707714000
            ],
            [
                27.11,
                1707800400
            ],
            [
                27.56,
                1707886800
            ],
            [
                28.66,
                1707973200
            ],
            [
                28.42,
                1708059600
            ],
            [
                28.05,
                1708405200
            ],
            [
                28.14,
                1708491600
            ],
            [
                27.935,
                1708578000
            ],
            [
                29.06,
                1708664400
            ],
            [
                29.5,
                1708923600
            ],
            [
                30.69,
                1709010000
            ],
            [
                31.08,
                1709096400
            ],
            [
                29.7,
                1709182800
            ],
            [
                31.01,
                1709269200
            ],
            [
                30.63,
                1709528400
            ],
            [
                30.35,
                1709614800
            ],
            [
                31.11,
                1709701200
            ],
            [
                30.81,
                1709787600
            ],
            [
                31.07,
                1709874000
            ],
            [
                32.43,
                1710129600
            ],
            [
                32.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7691,
        "drug_name": "TRODELVY (sacituzumab govitecan)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Urothelial Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-04-13",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210413006168\/en\/",
        "note": "FDA approval announced April 13, 2021.",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 1951,
        "drug_name": "OPDIVO (nivolumab)",
        "clinical_trial_id": "NCT02872116",
        "has_trial_insight_page": 0,
        "indication": "Gastric cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-04-16",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210416005465\/en\/",
        "note": "FDA approval announced April 16, 2021.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6824,
        "drug_name": "ZYNLONTA (Loncastuximab Tesirine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Diffuse Large B-Cell Lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-04-23",
        "link": "https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761196s000lbl.pdf",
        "note": "FDA approval announced April 23, 2021.",
        "company_entity_id": 785,
        "company_ticker": "ADCT",
        "company_name": "ADC Therapeutics SA",
        "company_price": "4.4500",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 1,
        "company_number_of_shares": 80642530,
        "price_change_sparkline": [
            [
                3.12,
                1706677200
            ],
            [
                3.6,
                1706763600
            ],
            [
                3.6,
                1706850000
            ],
            [
                3.65,
                1707109200
            ],
            [
                3.93,
                1707195600
            ],
            [
                4.11,
                1707282000
            ],
            [
                3.93,
                1707368400
            ],
            [
                4.36,
                1707454800
            ],
            [
                4.45,
                1707714000
            ],
            [
                4.22,
                1707800400
            ],
            [
                4.86,
                1707886800
            ],
            [
                4.97,
                1707973200
            ],
            [
                5.29,
                1708059600
            ],
            [
                4.82,
                1708405200
            ],
            [
                4.69,
                1708491600
            ],
            [
                4.89,
                1708578000
            ],
            [
                4.68,
                1708664400
            ],
            [
                5.14,
                1708923600
            ],
            [
                5.01,
                1709010000
            ],
            [
                4.86,
                1709096400
            ],
            [
                4.83,
                1709182800
            ],
            [
                4.86,
                1709269200
            ],
            [
                4.63,
                1709528400
            ],
            [
                4.82,
                1709614800
            ],
            [
                5,
                1709701200
            ],
            [
                4.97,
                1709787600
            ],
            [
                4.5,
                1709874000
            ],
            [
                4.45,
                1710129600
            ],
            [
                4.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2451,
        "drug_name": "FARXIGA (Dapagliflozin)",
        "clinical_trial_id": "NCT03036150",
        "has_trial_insight_page": 0,
        "indication": "Chronic Kidney Disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-04-30",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210430005617\/en\/",
        "note": "FDA approval announced April 30, 2021.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7773,
        "drug_name": "KEYTRUDA (pembrolizumab) and HERCEPTIN (Trastuzumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-05",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210505006075\/en\/",
        "note": "FDA approval announced May 5, 2021.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3345,
        "drug_name": "ZYNRELEF (HTX-011)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Post operative pain",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-13",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/heron-therapeutics-announces-us-fda-approval-of-zynrelef-htx-011-for-the-management-of-postoperative-pain-for-up-to-72-hours-301290467.html",
        "note": "FDA approval announced May 13, 2021.",
        "company_entity_id": 157,
        "company_ticker": "HRTX",
        "company_name": "Heron Therapeutics Inc.",
        "company_price": "2.3600",
        "company_change": -0.050000000000000044,
        "company_percent_change": -2.07,
        "company_optionable": 1,
        "company_number_of_shares": 150072640,
        "price_change_sparkline": [
            [
                2.41,
                1706677200
            ],
            [
                2.4,
                1706763600
            ],
            [
                2.39,
                1706850000
            ],
            [
                2.23,
                1707109200
            ],
            [
                2.32,
                1707195600
            ],
            [
                2.26,
                1707282000
            ],
            [
                2.35,
                1707368400
            ],
            [
                2.43,
                1707454800
            ],
            [
                2.63,
                1707714000
            ],
            [
                2.51,
                1707800400
            ],
            [
                2.72,
                1707886800
            ],
            [
                2.88,
                1707973200
            ],
            [
                2.87,
                1708059600
            ],
            [
                2.87,
                1708405200
            ],
            [
                2.75,
                1708491600
            ],
            [
                2.62,
                1708578000
            ],
            [
                2.6,
                1708664400
            ],
            [
                2.6,
                1708923600
            ],
            [
                2.74,
                1709010000
            ],
            [
                2.7,
                1709096400
            ],
            [
                2.66,
                1709182800
            ],
            [
                2.61,
                1709269200
            ],
            [
                2.555,
                1709528400
            ],
            [
                2.56,
                1709614800
            ],
            [
                2.48,
                1709701200
            ],
            [
                2.59,
                1709787600
            ],
            [
                2.6,
                1709874000
            ],
            [
                2.41,
                1710129600
            ],
            [
                2.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4935,
        "drug_name": "EMPAVELI (pegcetacoplan)",
        "clinical_trial_id": "NCT03500549",
        "has_trial_insight_page": 0,
        "indication": "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-14",
        "link": "https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-new-treatment-adults-serious-rare-blood-disease",
        "note": "FDA approval announced May 14, 2021.",
        "company_entity_id": 465,
        "company_ticker": "APLS",
        "company_name": "Apellis Pharmaceuticals Inc.",
        "company_price": "58.5000",
        "company_change": -2.19,
        "company_percent_change": -3.61,
        "company_optionable": 1,
        "company_number_of_shares": 120581749,
        "price_change_sparkline": [
            [
                63.29,
                1706677200
            ],
            [
                62.13,
                1706763600
            ],
            [
                62.56,
                1706850000
            ],
            [
                68.16,
                1707109200
            ],
            [
                67.31,
                1707195600
            ],
            [
                66.7,
                1707282000
            ],
            [
                68.12,
                1707368400
            ],
            [
                68.56,
                1707454800
            ],
            [
                67.75,
                1707714000
            ],
            [
                66.17,
                1707800400
            ],
            [
                67.39,
                1707886800
            ],
            [
                67.58,
                1707973200
            ],
            [
                68.78,
                1708059600
            ],
            [
                67.85,
                1708405200
            ],
            [
                66.89,
                1708491600
            ],
            [
                67.59,
                1708578000
            ],
            [
                68.47,
                1708664400
            ],
            [
                71.73,
                1708923600
            ],
            [
                69.35,
                1709010000
            ],
            [
                64.05,
                1709096400
            ],
            [
                61.97,
                1709182800
            ],
            [
                63.89,
                1709269200
            ],
            [
                64.63,
                1709528400
            ],
            [
                62.47,
                1709614800
            ],
            [
                60.94,
                1709701200
            ],
            [
                62.44,
                1709787600
            ],
            [
                61.63,
                1709874000
            ],
            [
                60.69,
                1710129600
            ],
            [
                58.5,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5432,
        "drug_name": "OPDIVO (nivolumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Esophageal or Gastroesophageal Junction Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-20",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210520005931\/en\/",
        "note": "FDA approval announced May 20, 2021.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2758,
        "drug_name": "MYFEMBREE (Relugolix, estradiol, norethindrone acetate)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Uterine fibroids",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-26",
        "link": "https:\/\/investors.myovant.com\/news-releases\/news-release-details\/myovant-sciences-and-pfizer-receive-fda-approval-myfembreer",
        "note": "FDA approval announced May 26, 2021.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6511,
        "drug_name": "Sotrovimab (VIR-7831 \/ GSK4182136) - (COMET-ICE)",
        "clinical_trial_id": "NCT04545060",
        "has_trial_insight_page": 0,
        "indication": "COVID-19 antibody",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-26",
        "link": "https:\/\/investors.vir.bio\/news-releases\/news-release-details\/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives",
        "note": "FDA Emergency Use Authorization filing approval announced May 26, 2021.",
        "company_entity_id": 316,
        "company_ticker": "XNCR",
        "company_name": "Xencor Inc.",
        "company_price": "22.8000",
        "company_change": -0.32999999999999996,
        "company_percent_change": -1.4300000000000002,
        "company_optionable": 1,
        "company_number_of_shares": 61120272,
        "price_change_sparkline": [
            [
                18.7,
                1706677200
            ],
            [
                19.06,
                1706763600
            ],
            [
                18.74,
                1706850000
            ],
            [
                18.79,
                1707109200
            ],
            [
                19.11,
                1707195600
            ],
            [
                18.7,
                1707282000
            ],
            [
                18.65,
                1707368400
            ],
            [
                19.42,
                1707454800
            ],
            [
                20.51,
                1707714000
            ],
            [
                19.12,
                1707800400
            ],
            [
                20.1,
                1707886800
            ],
            [
                21.3,
                1707973200
            ],
            [
                24.15,
                1708059600
            ],
            [
                23.5,
                1708405200
            ],
            [
                24.09,
                1708491600
            ],
            [
                24.39,
                1708578000
            ],
            [
                24.47,
                1708664400
            ],
            [
                25.87,
                1708923600
            ],
            [
                26.52,
                1709010000
            ],
            [
                22.79,
                1709096400
            ],
            [
                22.95,
                1709182800
            ],
            [
                23.82,
                1709269200
            ],
            [
                23.92,
                1709528400
            ],
            [
                22.85,
                1709614800
            ],
            [
                23.83,
                1709701200
            ],
            [
                23.79,
                1709787600
            ],
            [
                24.25,
                1709874000
            ],
            [
                23.13,
                1710129600
            ],
            [
                22.8,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6511,
        "drug_name": "Sotrovimab (VIR-7831 \/ GSK4182136) - (COMET-ICE)",
        "clinical_trial_id": "NCT04545060",
        "has_trial_insight_page": 0,
        "indication": "COVID-19 antibody",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-26",
        "link": "https:\/\/investors.vir.bio\/news-releases\/news-release-details\/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives",
        "note": "FDA Emergency Use Authorization filing approval announced May 26, 2021.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6511,
        "drug_name": "Sotrovimab (VIR-7831 \/ GSK4182136) - (COMET-ICE)",
        "clinical_trial_id": "NCT04545060",
        "has_trial_insight_page": 0,
        "indication": "COVID-19 antibody",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-26",
        "link": "https:\/\/investors.vir.bio\/news-releases\/news-release-details\/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives",
        "note": "FDA Emergency Use Authorization filing approval announced May 26, 2021.",
        "company_entity_id": 708,
        "company_ticker": "VIR",
        "company_name": "Vir Biotechnology Inc.",
        "company_price": "10.7300",
        "company_change": -0.6699999999999999,
        "company_percent_change": -5.88,
        "company_optionable": 1,
        "company_number_of_shares": 135032268,
        "price_change_sparkline": [
            [
                9.4,
                1706677200
            ],
            [
                9.12,
                1706763600
            ],
            [
                8.67,
                1706850000
            ],
            [
                8.6,
                1707109200
            ],
            [
                8.99,
                1707195600
            ],
            [
                9.06,
                1707282000
            ],
            [
                9.23,
                1707368400
            ],
            [
                9.29,
                1707454800
            ],
            [
                9.74,
                1707714000
            ],
            [
                8.85,
                1707800400
            ],
            [
                9.79,
                1707886800
            ],
            [
                10.31,
                1707973200
            ],
            [
                10.25,
                1708059600
            ],
            [
                10.23,
                1708405200
            ],
            [
                10.11,
                1708491600
            ],
            [
                10.3,
                1708578000
            ],
            [
                11.53,
                1708664400
            ],
            [
                11.9,
                1708923600
            ],
            [
                11.43,
                1709010000
            ],
            [
                11.6,
                1709096400
            ],
            [
                11.24,
                1709182800
            ],
            [
                11.24,
                1709269200
            ],
            [
                11.19,
                1709528400
            ],
            [
                10.88,
                1709614800
            ],
            [
                10.92,
                1709701200
            ],
            [
                11.26,
                1709787600
            ],
            [
                11.36,
                1709874000
            ],
            [
                11.4,
                1710129600
            ],
            [
                10.73,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3282,
        "drug_name": "PYLARIFY (piflufolastat F 18)",
        "clinical_trial_id": "NCT03739684",
        "has_trial_insight_page": 0,
        "indication": "Prostate cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-27",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210527005291\/en\/",
        "note": "FDA Approval announced May 27, 2021.",
        "company_entity_id": 187,
        "company_ticker": "LNTH",
        "company_name": "Lantheus Holdings Inc.",
        "company_price": "60.8800",
        "company_change": -1.84,
        "company_percent_change": -2.93,
        "company_optionable": 1,
        "company_number_of_shares": 68525556,
        "price_change_sparkline": [
            [
                51.93,
                1706677200
            ],
            [
                53.01,
                1706763600
            ],
            [
                54,
                1706850000
            ],
            [
                54.06,
                1707109200
            ],
            [
                54.99,
                1707195600
            ],
            [
                54.6,
                1707282000
            ],
            [
                55.56,
                1707368400
            ],
            [
                56.14,
                1707454800
            ],
            [
                56.55,
                1707714000
            ],
            [
                54.89,
                1707800400
            ],
            [
                56.37,
                1707886800
            ],
            [
                57.75,
                1707973200
            ],
            [
                57.46,
                1708059600
            ],
            [
                56.83,
                1708405200
            ],
            [
                56.71,
                1708491600
            ],
            [
                65.05,
                1708578000
            ],
            [
                66.27,
                1708664400
            ],
            [
                68.14,
                1708923600
            ],
            [
                68.26,
                1709010000
            ],
            [
                65.37,
                1709096400
            ],
            [
                65.38,
                1709182800
            ],
            [
                64.64,
                1709269200
            ],
            [
                65.36,
                1709528400
            ],
            [
                64.44,
                1709614800
            ],
            [
                61.97,
                1709701200
            ],
            [
                62.59,
                1709787600
            ],
            [
                62.52,
                1709874000
            ],
            [
                62.72,
                1710129600
            ],
            [
                60.88,
                1710216000
            ]
        ],
        "statuses": []
    }
]